EFFECTIVENESS, IMMUNOGENICITY, SAFETY AND PHARMACOECONOMIC ASPECTS FOLLOWING A SWITCH FROM REFERENCE INFLIXIMAB TO THE BIOSIMILAR SB2 IN INFLAMMATORY BOWEL DISEASE PATIENTS: A 6 MONTHS PROSPECTIVE COHORT STUDY

Sarah Fischer  1     Entcho Klenske  1     Heike Schmitt  1     Francesco Vitali  1     Simon Hirschmann  1     Franz Koch  1     Andreas Ramming  2     Sebastian Zundler     Sabine Krebs     Frank Dörje     Daniel Nagore     Sebastian Meyer     Wolfgang Uter     Markus F. Neurath     Raja Atreya    
1 University of Erlangen-Nürnberg,Erlangen,Germany
2 University of Erlangen-Nürnberg,Erl

Conference
UEG Week 2018

Citation
United European Gastroenterology Journal 2018; 6 (Supplement 1)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing